electroCore, Inc. to Present at the Evercore ISI HealthCONx Conference
20 Novembro 2018 - 7:05PM
electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a
commercial-stage bioelectronic medicine company, today announced
the company will be participating in the upcoming Evercore ISI
HealthCONx Conference in Boston, MA.
electroCore’s management is scheduled to present on Tuesday,
November 27, 2018 at 2:20 PM Eastern Time. Interested parties
may access a live and archived webcast of the presentation on the
“Investors” section of the company’s website at:
www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine
company dedicated to improving patient outcomes through its
platform non-invasive vagus nerve stimulation therapy initially
focused on the treatment of multiple conditions in neurology and
rheumatology. The Company’s initial targets are the acute treatment
of migraine and episodic cluster headache.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited
to, statements about electroCore's business prospects and product
development plans, its pipeline or potential markets for its
technologies, and other statements that are not historical in
nature, particularly those that utilize terminology such as
"anticipates," "will," "expects," "believes," "intends," other
words of similar meaning, derivations of such words and the use of
future dates. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue electroCore’s business and
product development plans, the inherent uncertainties associated
with developing new products or technologies, the ability to
commercialize gammaCore™, the willingness and degree of third-party
payors to provide adequate coverage and reimbursement for the use
of gammaCore, competition in the industry in which electroCore
operates, overall market conditions, and continuing positive trends
in prescriptions and user demand for our therapy. Any
forward-looking statements are made as of the date of this press
release, and electroCore assumes no obligation to update the
forward-looking statements or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should
consult all of the information set forth herein and should also
refer to the risk factor disclosure set forth in the reports and
other documents electroCore files with the SEC available at
www.sec.gov.
Contacts
Investors:Greg Chodaczek or Lynn LewisGilmartin
Groupinvestors@electrocore.com(646) 924-1769
or
Media:Alexandra Canale GCI Health(617)
921-9353alexandra.canale@gcihealth.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024